Breaking News

BMS, Reckitt in OTC Pact

February 12, 2013

BMS to market several OTC medicines in Latin America

Bristol-Myers Squibb has entered into a three-year collaboration agreement with Reckitt Benckiser Group for several of its OTC medicines currently sold in Latin America, primarily in Mexico and Brazil.
 
Bristol-Myers Squibb will receive an upfront payment of $438 million for the exclusive rights to sell, distribute and market the products for a three-year period. They include: Picot, an antacid, Tempra, a pain reliever and fever reducer, Micostatin, an antifungal, Graneodin, a cough and cold medicine, Dermodex, an anti-rash cream, Luftal, an anti-gas medicine, and Naldecon, a cold and flu symptoms treatment.
 
During the collaboration, BMS will retain responsibility for manufacturing all of the products (or use contract third party manufacturers), and Reckitt Benckiser will purchase products from BMS and pay royalties on product sales. BMS will also receive an option fee of $44 million for the right to purchase these products at the end of the three-year term.
 
“As part of our BioPharma strategy, Bristol-Myers Squibb has worked to focus its businesses around the world on innovative medicines in areas of high unmet medical need,” said Charles Bancroft, executive vice president, Intercontinental Region and Japan, and chief financial officer. “This agreement allows us to increase our focus on the launch and commercialization of our innovative portfolio in these important markets in Latin America.”
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision